MedTrace Logo

Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac® Hausstaubmilbe

NCT03127436 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2019-04-24

No results posted yet for this study

Summary

Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT therapy With Acarovac® Hausstaubmilbe

Conditions

  • Perennial Allergic Rhinitis

Interventions

DRUG

Acarovac

House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.

Sponsors & Collaborators

  • Bencard Allergie GmbH

    collaborator OTHER

  • University Hospital of Cologne

    lead OTHER

Principal Investigators

  • Matthias Kramer, Prof. Dr. · Bencard Allergie GmbH

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2019-02-14
Completion
2019-02-14

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03127436 on ClinicalTrials.gov